Silence Therapeutics (SLN) announced it secured $200 million in financing at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, bolstering its cash reserves to $272 million and extending its runway to approximately 2.5 to 3 years. The company remains debt-free, maintaining a current ratio of 7.42, and reported a 163% year-over-year stock return and 121% return over the past six months, despite a $1.27 per-share loss over the last twelve months. The capital raise follows promising Phase II data for its lead drug, Divesiran, which targets TMPRSS6 in polycythemia vera (PV) patients requiring phlebotomy treatment.
Silence Therapeutics Raises $200M as Divesiran Shows Strong Phase II Results for Polycythemia Vera
The biotech firm aims to expand its lead drug’s dosing regimen and accelerate development ahead of a potential $1B–$2B market opportunity.
SL
Sophie Laurent · FX & Rates Desk · 17 Sept 2026 · 21:33 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
SL
Written by
Sophie Laurent
FX & Rates Desk
Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.
More from Sophie Laurent →
